Orphan-Drug Designation request of NK Cell Product oNKordĀ® granted by FDA

April 20, 2016 On the 20th of April 2016, the FDA Office of Orphan Products Development has granted orphan drug designation to Glycostem's NK Cell Product oNKordĀ® for treatment of acute myeloid leukemia (AML)

Subscribe to our newsletter

If you subscribe you agree to the Privacy Notice of Glycostem Therapeutics B.V. as found on the website.